Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Minor· 25

Five-Day Antiviral Infusion Safe for Long COVID, ERASE Trial Finds

A UK feasibility study found that giving long COVID patients a five-day intravenous antiviral was safe and doable — and many reported less fatigue, better quality of life and longer walking distances. Researchers now want a bigger randomized trial to prove whether the drug actually works.

By the Paparazzi desk Caught by @breakwater128
Catcher · Silver
November 18, 2026 · 4:50 PM · medicalxpress.com · 1 view
Fact boxTrust 40/100 · Unverified
What we verified
  • Original source: medicalxpress.com.
  • The source published it on Nov 18, 2026 at 4:50 PM.
What we couldn't
  • Not verified by major outlets. This story may be false.
  • No second outlet has reported it yet. Treat it as a single-source claim.

The ERASE LC trial has cleared its first hurdle. Delivering a five-day intravenous antiviral treatment to people with long COVID — and running all the assessments needed to measure it — was safe and feasible, researchers report in Oxford Open Immunology. The team behind it is now pushing for a larger randomized controlled trial to find out whether the treatment truly helps.

Seventy-three patients went through assessments at specialist university facilities and at the University of Exeter before receiving the antiviral drug intravenously for five consecutive days. Clinical teams from University Hospitals of Derby and Burton NHS Foundation Trust and Royal Devon University Healthcare NHS Foundation Trust ran the treatment, in collaboration with Aston University. The study, an open-label feasibility trial of remdesivir, began in September 2024, roughly five years after the global COVID-19 pandemic started.

Sponsored

The trial wasn't built to prove the drug works, but the exploratory measures still turned heads. Most participants reported less fatigue, a better quality of life and increased distance in a timed walking test. Long COVID is estimated to affect more than 2 million people in the UK, with symptoms ranging from extreme fatigue and breathlessness to palpitations and brain fog.

Professor Mark Faghy, professor of clinical exercise science at Loughborough University and a visiting professor at the University of Derby, called the results an important step forward. He stressed that ERASE was not designed to show whether the treatment caused the changes — only that the setup works — and said the findings give a strong rationale for a bigger randomized trial that can answer the question properly.

Professor Victoria Allgar, professor of medical statistics and director of PenCTU, said the trial's successful completion shows why feasibility studies matter: recruitment, treatment delivery, data collection and participant follow-up all proved workable in people living with long COVID, laying the foundation for a definitive trial.

TopicsERASE LC trial · remdesivir · long COVID · Mark Faghy · Victoria Allgar · Loughborough University · University of Exeter · Oxford Open Immunology

Share

Source: medicalxpress.com

Written by AI from verified reporting.

More stories

  • Health & science 18:16 UTC · 47 minutes ago · theguardian.com · 0 views
    E coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise
  • Health & science 17:31 UTC · 2 hours ago · rarecancernews.com · 2 views
    EU approves Rasonque for previously treated metastatic pancreatic cancer
  • Health & science 15:47 UTC · 3 hours ago · dailycoffeenews.com · 2 views
    FDA Pullplug on Methylene Chloride Use, Decaf Ban Fight Continues
  • Health & science 15:31 UTC · 4 hours ago · wam.ae · 2 views
    UAE drug regulator: no medical ads without approval, influencer promos banned
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.